跳至主要内容

Medicilon Subsidiary Medicilon (Hangzhou) Inc. Grandly Opened!

 On September 7, 2022, the opening ceremony of Medicilon (Hangzhou) Inc., a subsidiary of Shanghai Medicilon Inc., was held in Hangzhou.

Medicilon (Hangzhou) will build as a CRO research center.  The nearly 8,000-square-meter R&D laboratory will focus on the biopharmaceuticals and AI pharmaceuticals, such as chemical drug synthesis research, compound synthesis, compound activity screening and other services.  This could accelerate the industrialization of research results.

Medicilon hangzhou.jpg

 

About Medicilon

Medicilon is an integrated contract research organization (CRO), providing comprehensive one-step new drug R&D for pharmaceutical enterprises and scientific research institutions around the world. We provide one-stop customized R&D solutions ranging from precise drug targeting to IND filing assistance. Deeply integrate R&D experience, constantly climb the peak of R&D technology, and build an integrated innovation service platform for new drug R&D.

 

Medicilon Medicinal Chemistry Services

At Medicilon, Our medicinal chemistry team is capable of flexibly applying computer chemistry to assist compound design process. In the meantime, we apply advanced drug discovery technologies, including proteolysis-targeting chimera (PROTAC), DNA-encoded chemical library (DEL) and antibody drug conjugation (ADC). We are also proud of our rich experience in innovative design and patent strategies that complement our technologies. In addition, our responsive project management and effective communication help optimize our project delivery.

 

Medicilon Synthetic Chemistry Services

Medicilon is proud of our extensive expertise in synthetic organic chemistry. With a team of over 1200 chemists, our synthetic chemistry department is capable of the independent design of synthesis pathways and complex compound treatments, key to helping accelerate our clients' drug discovery. As we pay great attention to scientific morality, we protect our clients' intellectual property rights tirelessly and guarantee data integrity. Furthermore, our projects are always undertaken with a fundamental focus on safety and green chemistry.

 

Services

 AI supported route design and process optimization;

 Custom chemical synthesis;

 Synthesis of standards, reference compounds, and molecular probes;

 Synthesis of high-quality compounds from milligram to kilogram;

 Synthesis and resolution of chiral compounds and so on.


Innovative Drug R&D Services

AI R&D Innovation

   As the first CRO stock on the Sci-tech Innovation Board, Medicilon is one of the companies that pay attention to AI technology in the industry at the beginning.  Currently, Medicilon uses deep neural network machine learning technology to construct a BTK inhibitor drug design model.  Medicilon also commits to establishing a molecular design and screening platform for BTK inhibitor drugs, launching “CRO+AI” to accelerate the development of new drugs.

Antibody-Drug Conjugate (ADC)

Medicilon offers clients with a pool of payload drugs of various mechanisms and offers custom synthesis of payload drugs. Medicilon fully understands the complexity of ADA evaluation and offers our clients with comprehensive immunogenicity assays.

Proteolysis Targeting Chimera (PROTAC)

Medicilon gathers the popular POI ligands and multiple tissue types of E3 ligase ligands, in addition of established a linker library containing hundreds of linking molecules. Medicilon has established a complete PROTAC in vitro analysis platform.

#PROTAC #AI #drugdiscovery


评论

此博客中的热门博文

Medicilon and Binhui Biopharmaceutical Have Reached a Strategic Collaboration to Jointly Draw a New Blueprint for the Development of New Biological Drugs

  On March 18, Medicilon and Binhui Biopharmaceutical (Binui Bio) announced a strategic collaboration.  The two parties will work together to jointly explore the possibilities in cutting-edge fields such as oncolytic viruses, nucleic acid drugs and protein drugs. Gather and Work Together to Create Advantages      Facilitate the Research and Development of Oncolytic Viruses, Nucleic Acids, Proteins and Other Drugs As a one-stop biopharmaceutical comprehensive preclinical R&D service CRO, Medicilon has been developing and accumulating for 20 years, always adhering to the spirit of innovation, and has successfully constructed bi/multi-specific antibodies,  ADCs ,  mRNA vaccines ,  small nucleic acid drugs ,  PROTAC , and  CGT technical service platform  that have helped 421 INDs obtain clinical approval.  It is this outstanding achievement that has earned Medicilon wide recognition in the industry and laid a solid foundation f...

A Nickel-Catalyzed Reductive Alkylation of Aryl Bromides and Chlorides for Sp3-Sp2 Bond Formation

  In 2012, a nickel-catalyzed reductive alkylation method of aryl bromides and chlorides was reported. Under the optimized conditions, a variety of aryl and vinyl bromides as well as active aryl chloride can be reductively coupled with alkyl bromides in high yields. The protocols were highly functional-group tolerant and the reactions were not air or moisture sensitive. The reaction showed different chemoselectivity than conventional cross-coupling reactions. Substrates bearing both anelectrophilic and nucleophilic carbon resulted in selective coupling at the electrophilic carbon (R-X) and no reaction occurred at the nucleophilic carbon (R-[M]). The 2010 Nobel Prize in Chemistry was awarded for the Pd-catalyzed cross-coupling, and in the past decade the progress in cross-coupling has not only had a significant impact on academic research but has also influenced the industrial synthetic application. The transition-metal-catalyzed union of nucleophilic organo-boronic acids with elect...

What is Toxicokinetics?

Toxicokinetics  is essentially the study of “how a substance gets into the body and what happens to it in the body”. Four processes are involved in toxicokinetics. The study of the kinetics (movement) of chemicals was originally conducted with pharmaceuticals and thus the term pharmacokinetics became commonly used. In addition, toxicology studies were initially conducted with drugs. However, the science of toxicology has evolved to include environmental and occupational chemicals as well as drugs. Toxicokinetics is thus the appropriate term for the study of the kinetics of all toxic substances. Frequently the terms  toxicokinetics ,  pharmacokinetics , or disposition may be found in the literature to have the same meaning. Disposition is often used in place of toxicokinetics to describe the time-course of movement of chemicals through the body (that is, how does the body dispose of a xenobiotic?). The disposition of a toxicant along with its’ biological reactivi...